Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and/or paclitaxel

Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and/or paclitaxel

AbstractBackground Glioblastoma (GBM) is a primary malignancy of the central nervous system and is classified as a grade IV astrocytoma by the World Health Organization (WHO). Although GBM rarely metastasizes, its prognosis remains poor. Moreover, the standard treatment for GBM, temozolomide (TMZ),...

Full description

Bibliographic Details
Main Authors: Munazza Ahmed, Ahlam M. Semreen, Alexander D. Giddey, Wafaa S. Ramadan, Raafat El-Awady, Nelson C. Soares, Waseem El-Huneidi, Yasser Bustanji, Mohammad A. Y. Alqudah, Karem H. Alzoubi, Mohammad H. Semreen
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Annals of Medicine
Subjects:
Cisplatin
glioblastoma
GBM
paclitaxel
proteomics
systems biology
Online Access:https://www.tandfonline.com/doi/10.1080/07853890.2024.2305308

Internet

https://www.tandfonline.com/doi/10.1080/07853890.2024.2305308

Similar Items